Erythropoietin Reduces Death and Neurodevelopmental Impairment in Neonatal Hypoxic-Ischemic Encephalopathy

Seung Jun Bang, MD, Juyoung Lee, MD, PhD, Ga Won Jeon, MD, PhD, and Yong Hoon Jun, MD, PhD

1Department of Pediatrics, Inha University Hospital, Incheon, Korea
2Department of Pediatrics, Inha University College of Medicine, Incheon, Korea

ABSTRACT

Purpose: Erythropoietin (EPO) is a promising neuroprotective drug. We investigated whether EPO has beneficial effects on neurodevelopmental outcomes in infants with hypoxic-ischemic encephalopathy (HIE).

Methods: We retrospectively reviewed the data of 56 infants with HIE born at or after 35 weeks of gestation who were admitted to Inha University Hospital between 2012 and 2021. Patients were divided into two groups based on EPO use and compared. In the EPO group, patients were administered 1,000 U/kg of EPO on days 1, 2, 3, 5, and 7, starting within 24 hours after birth. The primary outcome was death or neurodevelopmental impairment (NDI) at the age of 12 months.

Results: EPO was administered to 38 infants, and 18 did not receive EPO. Only 37.5% of patients with HIE (21/56) and 60% of patients with moderate-to-severe HIE (21/35) received therapeutic hypothermia. Among all patients with HIE, death or NDI (21.1% vs. 50.0%; odds ratio [OR], 0.09; 95% confidence interval [CI], 0.01 to 0.78; \( P = 0.029 \)) and brain injury on imaging (42.1% vs. 83.3%; OR, 0.16; 95% CI, 0.03 to 0.92; \( P = 0.040 \)) were significantly lower in the EPO group than in the control group. Among patients with moderate-to-severe HIE, brain injury on imaging (54.2% vs. 90.9%; OR, 0.04; 95% CI, 0.002 to 0.700; \( P = 0.027 \)) was significantly lower in the EPO group than in the control group.

Conclusion: EPO administration significantly reduced mortality and NDI in infants with HIE. EPO can be considered an adjunctive therapeutic agent for neonatal HIE.

Key Words: Hypoxia-ischemia, brain; Erythropoietin; Asphyxia neonatorum

INTRODUCTION

Hypoxic-ischemic encephalopathy (HIE) is a major cause of neonatal death and neurodevelopmental impairment (NDI)[1-3]. Because perinatal asphyxia is unpredictable and difficult to prevent, adequate and timely treatment of affected newborns is essential for
neuroprotective management of neonatal HIE\(^2\). Therapeutic hypothermia is the only proven treatment for neonatal HIE\(^2-4\). However, not all neonates with HIE are eligible for therapeutic hypothermia, and there are still cases of treatment failure.

Recently, erythropoietin (EPO) has been highlighted as a promising neuroprotective agent in neonatal HIE. In a hypoxic state, EPO production increases in brain cells, which plays an important role in neuroprotection and neuroregeneration in the central nervous system\(^5\). Furthermore, increasing evidence suggests that EPO administration reduces mortality and improves neurodevelopmental outcomes in infants with HIE\(^7\). The time has come to discuss the use of EPO for neonatal HIE in the real clinical situation in Korea. Therefore, we investigated whether EPO administration has a beneficial effect on mortality and neurodevelopmental outcomes in newborns with HIE.

MATERIALS AND METHODS

1. Participants

We retrospectively reviewed the data of infants with HIE born at a gestational age of ≥35 weeks who were admitted to the neonatal intensive care unit (NICU) of Inha University Hospital from 2012 to 2021. The inclusion criterion for HIE was altered levels of consciousness with perinatal asphyxia. Altered consciousness was defined as having at least one of the following: lethargy, stupor, coma, hyperalert state, hypotonia, abnormal reflexes including oculomotor or pupillary abnormalities, absent or weak suck, or clinical seizures\(^14\). Perinatal asphyxia was based on at least one of the following criteria: 10 minutes Apgar score of ≤5; the need for resuscitation at 10 minutes (i.e., chest compressions or endotracheal or mask ventilation); pH <7.00 or base deficit ≥12 mEq/L in capillary or venous blood within 60 minutes of birth\(^15\). The 56 infants included in the study were divided into two groups according to EPO use. Off-label EPO was administered as per the attending clinician’s discretion with the parents’ consent. In the EPO group (n=38), EPO was administered intravenously at a dose of 1,000 U/kg on days 1, 2, 3, 5, and 7 of life, starting within 24 hours after birth\(^12\). This study was approved by the Institutional Review Board (IRB) of Inha University Hospital (IRB no. 2022-05-017). The requirement for informed consent was waived by the board owing to the retrospective nature of the study.

2. Data collection

Baseline characteristic data, including sex, gestational age, birth weight, delivery type, birthplace, Apgar scores, initial results of capillary or venous gas analysis, serum lactic acid, and lactate dehydrogenase, were collected. HIE was classified as mild, moderate, or severe based on the modified Sarnat and Sarnat staging\(^14\). In addition, patients’ clinical courses during NICU admission, including seizures and therapeutic hypothermia, were reviewed. The primary outcome was death or NDI at 12 months. The secondary outcome was brain injury observed on imaging. NDI was defined as cerebral palsy, cognitive impairment, or severe visual or hearing impairment that required assistance at 12 months of age. Brain injuries were defined as any injury to at least one region of the brain, including the cortex, basal ganglia, thalamus, posterior limb of the internal capsule, white matter, brain stem, or cerebellum, identified on brain ultrasonography or brain magnetic resonance imaging (MRI). Brain ultrasonography was performed using an 8 to 12 MHz transducer during the 1st week of life by a radiologist blinded to the interventions. Coronal and sagittal sections were obtained using anterior fontanelles. Brain MRI with diffusion-weighted imaging was performed using SIGNATM (Architect-70, GE Healthcare, Chicago, IL, USA). All brain images were reviewed by two experienced radiologists who were blinded to the use of EPO. When more than one imaging study or report was available, the most severe report was selected.

3. Statistical analysis

Variables are expressed as median (interquartile range [IQR]) or number (%). We compared both groups using the Mann-Whitney U-test for continuous variables and Fisher’s exact test for categorical variables, as appropriate. Statistical analysis was performed using SPSS version 27.0 (IBM Corp., Armonk, NY, USA). Statistical significance was set at \(P<0.05\).

RESULTS

1. Total patients with HIE

Of the 56 patients with HIE, 38 received EPO, and 18 did not (Figure 1). A total of 35 (62.5%) infants, including 21 (60%) infants with mild HIE and 14 (40%) with moderate-to-severe HIE, did not receive therapeutic hypothermia. The reasons for not receiving hypothermia among patients with moderate-to-severe HIE were as follows: no equipment available (n=3), >6 hours after birth
received EPO, and 11 did not. There were no differences in gestational age, birth weight, sex, maternal age, or mode of delivery. The Apgar score at 1 minute was lower (median 3 [IQR, 1 to 4] vs. 5 [IQR, 3 to 6], \( P = 0.049 \)), whereas the pCO\(_2\) at the initial capillary blood gas analysis was higher (80.6 cmH\(_2\)O [IQR, 67.3 to 97.3] vs. 51.3 cmH\(_2\)O [IQR, 23.5 to 76.3], \( P = 0.025 \)) in the EPO group than in the control group (Table 1). Serum lactic acid levels were higher and lactate dehydrogenase levels were lower in the EPO group (12.6 mmol/L [IQR, 6.2 to 13.3] vs. 4.7 mmol/L [IQR, 2.1 to 6.9], \( P = 0.025 \); and 632 U/L [IQR, 465 to 943] vs. 1,066 U/L [IQR, 912 to 1,244], \( P = 0.047 \); respectively) than in the control group (Table 1). Death or NDI at 12-month-of-age was lower in the EPO group (37.5% vs. 72.7%, \( P = 0.050 \); OR, 4.6; 95% CI, 0.30 to 70.10; \( P = 0.272 \)) (Tables 1, 2). Brain injury on imaging was significantly lower in the EPO group (42.1% vs. 83.3%, \( P = 0.004 \); OR, 0.16; 95% CI, 0.03 to 0.92; \( P = 0.040 \)) than in the control group.

2. Patients with moderate-to-severe HIE

Of the 35 included patients with moderate-to-severe HIE, 24 received EPO, and 11 did not. There were no differences in gestational age, birth weight, sex, maternal age, or mode of delivery. The Apgar score at 1 minute was lower (median 2 [IQR, 1 to 4] vs. 5 [IQR, 3 to 5], \( P = 0.049 \)), whereas the pCO\(_2\) at the initial capillary blood gas analysis was higher (80.6 cmH\(_2\)O [IQR, 67.3 to 97.3] vs. 51.3 cmH\(_2\)O [IQR, 23.5 to 76.3], \( P = 0.025 \)) in the EPO group than in the control group (Table 1). Serum lactic acid levels were higher and lactate dehydrogenase levels were lower in the EPO group (12.6 mmol/L [IQR, 6.2 to 13.3] vs. 4.7 mmol/L [IQR, 2.1 to 6.9], \( P = 0.025 \); and 632 U/L [IQR, 465 to 943] vs. 1,066 U/L [IQR, 912 to 1,244], \( P = 0.047 \); respectively) than in the control group (Table 1). The proportion of infants who received therapeutic hypothermia was not different between groups (70.8% vs. 36.4%, \( P = 0.073 \)). The frequency of clinical seizures did not differ (79.2% vs. 72.7%, \( P = 0.689 \)); nor did the mortality rate (25.0% vs. 36.4%, \( P = 0.689 \)).

Death or NDI at 12-month-of-age was lower in the EPO group than in the control group; however, the difference was not statistically significant (37.5% vs. 72.7%, \( P = 0.050 \); OR, 4.6; 95% CI, 0.30 to 70.10; \( P = 0.272 \)) (Tables 1, 2). Brain injury on imaging was significantly lower in the EPO group (54.2% vs. 90.9%, \( P = 0.034 \); OR, 0.04; 95% CI, 0.002 to 0.70; \( P = 0.027 \)) than in the control group.

DISCUSSION

Therapeutic hypothermia is the only proven treatment to reduce
mortality and neurodevelopmental disabilities in patients with HIE. However, many infants with HIE have poor prognoses even after hypothermia treatment\(^2,3\)\(^{,4,16}\). In addition, not all patients with HIE or birth asphyxia are eligible for therapeutic hypothermia because there is no available equipment or the patient does not meet the criteria of narrow indications (i.e., only for moderate-to-severe HIE, ≥36 weeks of gestation, ≥1,800 to 2,000 g of birth weight, <6 hours of age, and without coagulopathy)\(^3,15\). In this retrospective study, we found that EPO administration significantly improved mortality and neurodevelopmental outcomes in neonates with HIE. We also showed that only 37.5% (21/56) of neonates with HIE received hypothermia treatment (Figure 1). Many infants with HIE could not receive hypothermia treatment because of the mild stage of HIE (37.5%, 21/56) and various causes, even if they had moderate-to-severe HIE (25%, 14/56). For those unable to receive hypothermia, no brain-focused treat-

### Table 1. Comparisons of Neonates with Hypoxic-Ischemic Encephalopathy

<table>
<thead>
<tr>
<th>Variable</th>
<th>Total HIE (n=56)</th>
<th>Moderate-to-severe HIE (n=35)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>EPO (n=38)</td>
<td>Control (n=18)</td>
</tr>
<tr>
<td>Gestational age (wk)</td>
<td>38(37–39)</td>
<td>38(37–39)</td>
</tr>
<tr>
<td>Birth weight (g)</td>
<td>3,300(2,275–3,480)</td>
<td>3,020(2,710–3,275)</td>
</tr>
<tr>
<td>Sex, boy:girl</td>
<td>22:16 (57.9:42.1)</td>
<td>11.7 (61.1:38.9)</td>
</tr>
<tr>
<td>Born outside</td>
<td>25 (65.8)</td>
<td>15 (83.3)</td>
</tr>
<tr>
<td>Cesarean section</td>
<td>30 (78.9)</td>
<td>10 (55.6)</td>
</tr>
<tr>
<td>Maternal age (yr)</td>
<td>36 (30–38)</td>
<td>34 (31–35)</td>
</tr>
<tr>
<td>Apgar score 1 min</td>
<td>3 (1–5)</td>
<td>5 (3–6)</td>
</tr>
<tr>
<td>Apgar score 5 min</td>
<td>6 (3–7)</td>
<td>7 (5–9)</td>
</tr>
<tr>
<td>Initial blood gas analysis</td>
<td></td>
<td></td>
</tr>
<tr>
<td>pH</td>
<td>7.03 (6.91–7.13)</td>
<td>7.16 (7.00–7.21)</td>
</tr>
<tr>
<td>pCO(_2) (cmH(_2)O)</td>
<td>69.7 (64.8–86.5)</td>
<td>58.8 (33.5–68.5)</td>
</tr>
<tr>
<td>base deficit (mEq/L)</td>
<td>14.1 (9.1–19.8)</td>
<td>14.0 (4.0–20.6)</td>
</tr>
<tr>
<td>Serum lactic acid (mmol/L)</td>
<td>8.9 (6.0–12.8)</td>
<td>5.2 (4.5–6.2)</td>
</tr>
<tr>
<td>Serum LDH (U/L)</td>
<td>643 (455–879)</td>
<td>847 (608–1,155)</td>
</tr>
<tr>
<td>HIE stage</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mild</td>
<td>14 (36.8)</td>
<td>7 (38.9)</td>
</tr>
<tr>
<td>Moderate</td>
<td>17 (44.7)</td>
<td>7 (38.9)</td>
</tr>
<tr>
<td>Severe</td>
<td>7 (18.4)</td>
<td>4 (22.2)</td>
</tr>
<tr>
<td>Seizure</td>
<td>20 (52.6)</td>
<td>8 (44.4)</td>
</tr>
<tr>
<td>Hypothermia</td>
<td>19 (50)</td>
<td>4 (22.2)</td>
</tr>
<tr>
<td>Brain injury on imaging</td>
<td>16 (42.1)</td>
<td>15 (83.3)</td>
</tr>
<tr>
<td>Death</td>
<td>6 (15.8)</td>
<td>4 (22.2)</td>
</tr>
<tr>
<td>NDI</td>
<td>5 (13.2)</td>
<td>6 (33.3)</td>
</tr>
<tr>
<td>Death or NDI</td>
<td>8 (21.1)</td>
<td>9 (50.0)</td>
</tr>
</tbody>
</table>

Values are expressed as median (interquartile range) or number (%). Abbreviations: HIE, hypoxic-ischemic encephalopathy; EPO, erythropoietin; LDH, lactate dehydrogenase; NDI, neurodevelopmental impairment.

### Table 2. Multivariable Logistic Regression Analysis

<table>
<thead>
<tr>
<th>Variable</th>
<th>Total HIE* OR (95% CI)</th>
<th>P-value</th>
<th>Moderate-to-severe HIE* OR (95% CI)</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Brain injury on imaging</td>
<td>0.16 (0.03–0.92)</td>
<td>0.040</td>
<td>0.04 (0.002–0.70)</td>
<td>0.027</td>
</tr>
<tr>
<td>Death or NDI</td>
<td>0.09 (0.01–0.78)</td>
<td>0.029</td>
<td>0.32 (0.03–3.70)</td>
<td>0.360</td>
</tr>
</tbody>
</table>

*Adjusted for Apgar score 1 and 5 minutes, pH and pCO\(_2\) of initial blood gas analysis, and hypothermia; \(^3\)Adjusted for Apgar score 1 minute, pCO\(_2\) of initial blood gas analysis, serum lactic acid and lactate dehydrogenase, and hypothermia.

Abbriviations: HIE, hypoxic-ischemic encephalopathy; OR, odds ratio; CI, confidence interval; NDI, neurodevelopmental impairment.
ment, rather only conventional intensive care, including respiratory support, fluid infusion, anticonvulsants, inotropic support, and correction of metabolic or electrolyte imbalance, was provided. In this regard, our results suggest that EPO could be considered an important therapeutic agent to provide neuroprotection with or without hypothermia.

EPO is a glycoprotein that is primarily responsible for red blood cell production. Owing to this effect, it has been clinically used for decades to treat or prevent anemia of prematurity, and there have been no complications in neonates. The key neuroprotective mechanism of EPO is known to involve the repair of the nervous system; EPO stimulates neurogenesis, oligodendrogenesis, and angiogenesis following hypoxic brain injury. Additionally, EPO increases neuronal and glial migration around the injured area via the secretion of matrix metalloproteinases in vitro. Based on the results of animal studies that showed that the early administration of high-dose EPO was both neuroprotective and neurorestorative, EPO has emerged as an attractive treatment option for neonatal HIE since the early 2000s. Since then, several studies on term or preterm infants with HIE have reported that EPO administration decreased mortality and improved long-term neurological outcomes. Potential adverse effects of EPO include polycythemia and thrombosis. However, during more than 10 years of clinical trials in neonates, no obvious side effects or serious adverse events were observed with EPO administration. Although EPO administration route, dosage, starting point, frequency of injections, and length of treatment vary, EPO appears to be a promising treatment modality for neonatal HIE without the risk of undesirable side effects. However, the prophylactic use of EPO for neuroprotection in preterm infants remains controversial. Although a meta-analysis of four studies performed in preterm infants showed cognitive improvement, a recent large-scale randomized trial regarding the use of prophylactic high-dose EPO in extremely preterm infants did not show advantages in terms of mortality or neurodevelopmental outcomes.

This study has some limitations. First, the data were collected from a single center and analyzed retrospectively. Second, the number of patients was small, especially for moderate-to-severe HIE. This might lower the power to prove the benefit of EPO on death or NDI in patients with moderate-to-severe HIE. Larger prospective studies should address this issue. Third, we included all patients with HIE, from mild to severe cases, rather than including only patients with moderate-to-severe HIE who received therapeutic hypothermia. As reported in this study, a significant number of neonatal HIE cases were not clinically indicated for therapeutic hypothermia. Because this study was not a randomized controlled study, we aimed to reflect real clinical situations. Fourth, EPO was administered off-label at the attending clinician’s discretion and not as per planned protocols. However, we decided to use EPO based on convincing evidence of the effectiveness of EPO for neonatal HIE, and EPO has been safely used for decades in infants. During the discussion with parents on EPO administration, every parent agreed to the off-label use of EPO, which could be beneficial in such a desperate state of their baby. Additionally, since off-label use of EPO is not costly, it is not a significant financial burden for most parents in Korea. We believe that now is not the time to discuss whether EPO should be used for neonatal HIE, but to determine the most effective dose, starting point, frequency, and length of EPO treatment for infants with HIE.

To our knowledge, this is the first study to investigate the clinical benefits of EPO administration for neonatal HIE in Korea. We demonstrated that EPO significantly reduced brain injuries in imaging studies and death or long-term NDI in neonatal HIE. We also found that a significant proportion of neonatal HIE cases were not clinically indicated for therapeutic hypothermia for various reasons. EPO can be valuable and, in some cases, the only treatment option to promote neuroprotection, especially for these infants. In conclusion, EPO is a promising therapeutic agent for neonatal HIE. Further large-scale prospective studies are required to address detailed guidelines for the optimal use of EPO for neonatal HIE.

**ARTICLE INFORMATION**

**Ethical statement**

The study was approved by the Institutional Review Board of Inha University Hospital (IRB no. 2022-05-017). The requirement for informed consent was waived by the board due to the retrospective nature of this study.

**Conflicts of interest**

No potential conflict of interest relevant to this article was reported.
Author contributions
Conception and design: J.L.
Acquisition, analysis, or interpretation of data: S.J.B., J.L., G.W.J., Y.H.J.
Drafting the work or revising: S.J.B., J.L.
Final approval of the manuscript: All authors read and approved the final version of the manuscript.

ORCID
Seung Jun Bang https://orcid.org/0000-0003-4474-1743
Juyoung Lee https://orcid.org/0000-0001-7548-2284
Ga Won Jeon https://orcid.org/0000-0002-8206-9727
Yong Hoon Jun https://orcid.org/0000-0002-0145-3306

Funding
This work was supported by a 2022 Inha University Hospital Research Grant.

Acknowledgments
None

REFERENCES
21. Ohlsson A, Aher SM. Early erythropoietin for preventing red blood cell transfusion in preterm and/or low birth weight infants.


